Multiple sclerosis—a quiet revolution

Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event

(2014) Darin T. Okuda et al.   PLoS One

B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

(2014) J. N. H. Stern et al.   Science Translational Medicine

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

(2013) Luca Prosperini et al.   Multiple Sclerosis Journal

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

(2013) Ashley H Beecham et al.   NATURE GENETICS

Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus

(2013) L. Ottoboni et al.   NEUROLOGY

Mortality in patients with multiple sclerosis

(2013) A. Scalfari et al.   NEUROLOGY

JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis

(2013) Eugene O. Major et al.   NEW ENGLAND JOURNAL OF MEDICINE

A clinical conundrum: the detrimental effect of TNF antagonists in multiple sclerosis

(2013) Calliope A Dendrou et al.   PHARMACOGENOMICS

Cortical remyelination: A new target for repair therapies in multiple sclerosis

(2012) Ansi Chang et al.   ANNALS OF NEUROLOGY

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta

(2012) Robert A. Bermel et al.   ANNALS OF NEUROLOGY

Benign Multiple Sclerosis: Does it exist?

(2012) Jorge Correale et al.   Current Neurology and Neuroscience Reports

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Low degree of cortical pathology is associated with benign course of multiple sclerosis

(2012) Massimiliano Calabrese et al.   Multiple Sclerosis Journal

Survival in MS

(2012) D.S. Goodin et al.   NEUROLOGY

Association of MRI metrics and cognitive impairment in radiologically isolated syndromes

(2012) M. P. Amato et al.   NEUROLOGY

Humoral-Targeted Immunotherapies in Multiple Sclerosis

(2012) Sabeen Lulu et al.   Neurotherapeutics

Interferon Beta and Glatiramer Acetate Therapy

(2012) Corey A. McGraw et al.   Neurotherapeutics

Fingolimod for Multiple Sclerosis

(2012) Daniel Pelletier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

An RNA Profile Identifies Two Subsets of Multiple Sclerosis Patients Differing in Disease Activity

(2012) L. Ottoboni et al.   Science Translational Medicine

Immune-mediated disease genetics: the shared basis of pathogenesis

(2012) Chris Cotsapas et al.   TRENDS IN IMMUNOLOGY

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

(2011) Owain W. Howell et al.   BRAIN

Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity

(2011) Xin Chen et al.   FEBS LETTERS

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo

(2011) Yinghui Hu et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

(2011) Ludwig Kappos et al.   Multiple Sclerosis Journal

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors

(2011) Andrew J Solomon et al.   Multiple Sclerosis Journal

A case of multiple sclerosis presenting with inflammatory cortical demyelination

(2011) B. F. G. Popescu et al.   NEUROLOGY

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome

(2011) D. T. Okuda et al.   NEUROLOGY

Inflammatory Cortical Demyelination in Early Multiple Sclerosis

(2011) Claudia F. Lucchinetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis

(2010) Roberta Magliozzi et al.   ANNALS OF NEUROLOGY

The use of ustekinumab in autoimmune disease

(2010) Caitriona Ryan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Humoral autoimmunity in multiple sclerosis

(2010) Edgar Meinl et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

PML risk and natalizumab: more questions than answers

(2010) Richard M Ransohoff   LANCET NEUROLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natalizumab in the treatment of multiple sclerosis

(2010) Brandon Brown   Therapeutics and Clinical Risk Management

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

(2009) M. Trojano et al.   ANNALS OF NEUROLOGY

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

(2009) M. Comabella et al.   BRAIN

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Benign or not benign MS: A role for routine neuropsychological assessment?

(2009) R. H.B. Benedict et al.   NEUROLOGY

Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis

(2009) E. Portaccio et al.   NEUROLOGY

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study

(2008) M Calabrese et al.   Multiple Sclerosis Journal

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE